Combinations ;
1. Betamethasone (oral)
2. Betamethasone / Dexchlorpheniramine
3. Betamethasone / Gentamicin ear & eye drops
4. Betamethasone / Gentamicin eye & ear drops
5. Betamethasone / Neomycin ear (also eye) drops
6. Betamethasone / Neomycin eye (also ear) drops
7. Betamethasone Acetate / Betamethasone Disodium Phosphate
8. Betamethasone dipropionate (skin)
9. Betamethasone Dipropionate / Gentamycin
10. Betamethasone dipropionate/Betamethasone sodium phosphate (parenteral)
11. Betamethasone eye/ear/nose drops
12. Betamethasone Valerate
13. Betamethasone Valerate/ Fusidic Acid
14. Betamethasone Valerate/ Neomycin
15. Betamethasone Valerate/Gentamycin
| 1. Betamethasone (oral) | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Allergic conditions; rheumatic arthritis; nephrotic syndrome; collagen diseases; fulminating SLE; bronchial asthma; status asthmaticus; severe chronic bronchial asthma; chronic ulcerative colitis; thrombocytopenia; organ transplant; shock (cardiogenic / traumatic). |
| Precautions | Patient monitor if used for prolonged use; use the lowest possible dose; use with caution in patients suffering from diabetes mellitus; CCF; hypertension; infections; thrombo-embolism; elderly; ureamia; and chronic renal failure. |
| Contra-Indications | Hypersensitivity to the drug; systemic fungal infections; live virus vaccination; IM use in idiopathic thrombocytopenic purpura; peptic ulceration; psychosis; osteoporosis; severe psychoneurosis; TB; ocular herpes simplex; primary glaucoma. |
| Side Effects | Hypertension; hypersensitivity reactions; muscle mass loss; osteoporosis; thrombo-embolism; thrombophlebitis; cardiac arrhythmias; insomnia; fatigue; hyperglyceamia; glaucoma; cushoid states; steroid psychosis and aggravation of pre-existing psychiatric conditions; syncopal episodes; GI disorders; impaired wound healing; thin fragile skin; acne; hirsutism; increased appetite and weight gain; convulsions; pancreatitis; spontaneous fractures; increased susceptibility to infections; peptic ulcerati |
| Dosage | 0.5-5mg daily. 1.M injection or slow 1.V inj or infusion. 4-20mg up to QID. Children up to 1 year; 1mg. 1-5 years; 2mg. 6-12 years; 4mg up to QID. |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Corticosteroids and related drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Betacort | Biopharma Laboratories Ltd. | Maxim Pharmaceuticals Ltd | 0.05% | 20g | Cream | KES 40.00 |
| 2. Betamethasone / Dexchlorpheniramine | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Allergic and inflammatory conditions |
| Precautions | see under Betamethasone and Dexchlorpheniramine respectively |
| Contra-Indications | see under Betamethasone and Dexchlorpheniramine respectively |
| Side Effects | see under Betamethasone and Dexchlorpheniramine respectively |
| Dosage | 1-2 tabs QID |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Corticosteroids and related drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Alerset | Centaur Pharmaceuticals Ltd. | Sai Pharmaceuticals Ltd. | 0.25mg/2mg | 30 | Tablet | per tablet | KES 304.00 |
| Celestamine | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.25mg/2mg | 30 | Tablet | per tablet | KES 450.00 |
| Neugen | Sphinx Pharmaceuticals Ltd | Sphinx Pharmaceuticals Ltd | 0.25mg/2mg | 30 | Tablet | per tablet | KES 180.00 |
| 3. Betamethasone / Gentamicin ear & eye drops | |
|---|---|
| Drug Indication | Inflammatory ear conditions with possible or presence of bacterial infections |
| Precautions | For short use only |
| Contra-Indications | Fungal, viral, TB and purulent infections, pregnancy, perforation of eardrum |
| Side Effects | Adrenal suppression especially in infants, super-infection, local irritation |
| Dosage | 3-4 drops 2-4 times daily. Saturated wick may be used and changed daily. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Drugs acting in the ear |
| 4. Betamethasone / Gentamicin eye & ear drops | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Inflammatory eye conditions with possible or presence of bacterial infections |
| Precautions | Avoid premature discontinuation, history of herpex simplex infections, and possibility of induction of corneal abscess, glaucoma, and fungal keratopathy. |
| Contra-Indications | Fungal, viral, TB and purulent infections, pregnancy, perforation of eardrum |
| Side Effects | Adrenal suppression especially in infants, super-infection, local irritation |
| Drug Category | OPHTHALMIC DRUGS |
| Drug Sub-Category | Antibacterial/steroid ophthalmic drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Bentogen ear drops | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 0.1%/0.3% | 10ml | ear drops | KES 50.00 | |
| Garasone | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 1mg/3mg | 5ml | ear drops | KES 305.00 | |
| Garasone | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 5ml | eye drops | per ml | KES 516 |
| 5. Betamethasone / Neomycin ear (also eye) drops | |
|---|---|
| Drug Indication | Inflammatory ear /eye conditions with possible or presence of bacterial infections |
| Precautions | For short use only |
| Contra-Indications | Fungal, viral, TB and purulent infections, pregnancy, perforation of eardrum |
| Side Effects | Adrenal suppression especially in infants, super-infection, local irritation |
| Dosage | 3-4 drops after 2-3 hours |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Drugs acting in the ear |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Ivebetaneocin | Ivee Aqua EPZ Ltd. | Harley's Limited | 0.1%/0.35% | 10ml | ear drops | KES 75.00 | |
| Probeta-N | Globe Pharmacy Ltd., | Globe Pharmacy Ltd., | 0.1%/0.5% | 7.5ml | ear drops | KES 78.75 |
| 6. Betamethasone / Neomycin eye (also ear) drops | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Inflammatory eye conditions with possible or presence of bacterial infections |
| Precautions | For short use only |
| Contra-Indications | Fungal, viral, TB and purulent infections, pregnancy, perforation of eardrum |
| Side Effects | Adrenal suppression especially in infants, super-infection, local irritation |
| Dosage | 1 or 2 drops 1-2 hourly or 0.5cm ointment BD or TID and /or at night. Ear: 2-3 drops 2 or 3 hourly. Nose: 2-3 drops in each nostril BD or TID. |
| Special Information | The indiscriminate prescription of steroid for undiagnosed Red eye should be avoided as this may be caused by Herpes Simplex virus. The condition is aggravated by steroids. |
| Drug Category | OPHTHALMIC DRUGS |
| Drug Sub-Category | Antibacterial/steroid ophthalmic drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Bentopic - N | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 0.1%/0.5% | 10ml | ear drops | KES 50.00 | |
| Laeovate-N | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 0.1%/0.5% | 5ml | ear drops | KES 47.00 | |
| Laeovate-N | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 0.1%/0.5% | 7.5ml | ear drops | KES 50.00 | |
| Probeta-N | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 0.1%/0.5% | 7.5ml | ear drops | KES 67.50 | |
| Probeta-N | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 0.1%/0.5% | 7.5ml | KES 74.25 | ||
| Probeta-N | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 5g | eye ointment | KES 74.25 |
| 7. Betamethasone Acetate / Betamethasone Disodium Phosphate | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Allergic conditions; rheumatic arthritis; nephrotic syndrome; collagen diseases; fulminating SLE; bronchial asthma; status asthmaticus; severe chronic bronchial asthma; chronic ulcerative colitis; thrombocytopenia; organ transplant; shock (cardiogenic / traumatic). |
| Precautions | Patient monitor if used for prolonged use; use the lowest possible dose; use with caution in patients suffering from diabetes mellitus; CCF; hypertension; infections; thrombo-embolism; elderly; ureamia; and chronic renal failure. |
| Contra-Indications | Hypersensitivity to the drug; systemic fungal infections; live virus vaccination; IM use in idiopathic thrombocytopenic purpura; peptic ulceration; psychosis; osteoporosis; severe psychoneurosis; TB; ocular herpes simplex; primary glaucoma. |
| Side Effects | Hypertension; hypersensitivity reactions; muscle mass loss; osteoporosis; thrombo-embolism; thrombophlebitis; cardiac arrhythmias; insomnia; fatigue; hyperglyceamia; glaucoma; cushoid states; steroid psychosis and aggravation of pre-existing psychiatric conditions; syncopal episodes; GI disorders; impaired wound healing; thin fragile skin; acne; hirsutism; increased appetite and weight gain; convulsions; pancreatitis; spontaneous fractures; increased susceptibility to infections; peptic ulcerati |
| Dosage | 0.5-5mg daily. 1.M injection or slow 1.V inj or infusion. 4-20mg up to QID. Children up to 1 year; 1mg. 1-5 years; 2mg. 6-12 years; 4mg up to QID. |
| Special Information | Betamethasone sodium phosphate, a soluble ester, provides prompt activity, while betamethasone acetate is only slightly soluble and provides sustained activity. Anti-inflammatory effects may appear within 1-3 hours and may persist for 7 days after I.M administration of the combination |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Corticosteroids and related drugs |
| 8. Betamethasone dipropionate (skin) | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Relief of some inflammatory conditions when potentially less harmful measures are ineffective |
| Precautions | Limit use in children or on face to maximum of 5 days. It should be withdrawn gradually following prolonged therapy. Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci. |
| Contra-Indications | Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use. |
| Side Effects | Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension. |
| Dosage | Apply thinly BD reducing strength and frequency as the condition responds |
| Drug Category | DERMATOLOGICAL PREPARATIONS |
| Drug Sub-Category | Topical Corticosteroids |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Tasone | Centaur Pharmaceuticals Ltd. | Sai Pharmaceuticals Ltd. | 0.065%, | 15gm | Cream | KES 41.00 |
| 9. Betamethasone Dipropionate / Gentamycin | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Steroid responsive dermatoses complicated or likely to be complicated by bacterial infections |
| Precautions | Limit use in children or on face to maximum of 5 days. It should be withdrawn gradually following prolonged therapy. Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci. |
| Contra-Indications | Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use. |
| Side Effects | Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension. |
| Dosage | Apply sparingly BD or TID |
| Drug Category | DERMATOLOGICAL PREPARATIONS |
| Drug Sub-Category | Topical Steroid/ Antibacterials |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Diprogenta | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.5mg/1mg | 15gm | Cream | KES 520.00 | |
| Diprogenta | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.5mg/1mg | 15gm | Ointment | KES 520.00 |
| 10. Betamethasone dipropionate/Betamethasone sodium phosphate (parenteral) | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Allergic conditions; rheumatic arthritis; nephrotic syndrome; collagen diseases; fulminating SLE; bronchial asthma; status asthmaticus; severe chronic bronchial asthma; chronic ulcerative colitis; thrombocytopenia; organ transplant; shock (cardiogenic / traumatic). |
| Precautions | Patient monitor if used for prolonged use; use the lowest possible dose; use with caution in patients suffering from diabetes mellitus; CCF; hypertension; infections; thrombo-embolism; elderly; ureamia; and chronic renal failure. |
| Contra-Indications | Hypersensitivity to the drug; systemic fungal infections; live virus vaccination; IM use in idiopathic thrombocytopenic purpura; peptic ulceration; psychosis; osteoporosis; severe psychoneurosis; TB; ocular herpes simplex; primary glaucoma. |
| Side Effects | Hypertension; hypersensitivity reactions; muscle mass loss; osteoporosis; thrombo-embolism; thrombophlebitis; cardiac arrhythmias; insomnia; fatigue; hyperglyceamia; glaucoma; cushoid states; steroid psychosis and aggravation of pre-existing psychiatric conditions; syncopal episodes; GI disorders; impaired wound healing; thin fragile skin; acne; hirsutism; increased appetite and weight gain; convulsions; pancreatitis; spontaneous fractures; increased susceptibility to infections; peptic ulcerati |
| Dosage | 0.5-5mg daily. 1.M injection or slow 1.V inj or infusion. 4-20mg up to QID. Children up to 1 year; 1mg. 1-5 years; 2mg. 6-12 years; 4mg up to QID. |
| Special Information | Betamethasone sodium phosphate, a soluble ester, provides prompt activity, while betamethasone dipropionate is only slightly soluble and provides sustained activity. Its duration of action is from 2 hours to more than 4 weeks. |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Corticosteroids and related drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Diprofos | Essex Chemie (See also Schering-Plough Corporation) | Laborex Kenya Eurapharma Ltd | 5mg / 2mg | 2ml | Injection | KES 556 |
| 11. Betamethasone eye/ear/nose drops | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Steroid responsive ocular inflammation |
| Precautions | Avoid premature discontinuation, history of herpex simplex infections, and possibility of induction of corneal abscess, glaucoma, and fungal keratopathy. |
| Contra-Indications | Fungal, viral and bacterial infections, ocular TB, glaucoma, ophthalmic ulceration/ laceration /abrasion |
| Side Effects | Secondary glaucoma, defects in visual acuity and visual field, cataract formation after prolonged use, coneal ulceration on prolonged use, coneal perforation in presence of diseases that causes corneal thinning, delay wound healing, development and spreading of bacterial/ viral / bacterial infections. |
| Dosage | Eye: Adults and Children: 2 or 3 drops two or three hourly. Nose: Adults and children: 2-3 drops in each nostril two to three times daily. |
| Special Information | The indiscriminate prescription of steroid for undiagnosed Red eye should be avoided as this may be caused by Herpes Simplex virus. The condition is aggravated by steroids. |
| Drug Category | OPHTHALMIC DRUGS |
| Drug Sub-Category | Steroid-only ophthalmic drugs |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Ivybetasone | Ivee Aqua EPZ Ltd. | Harley's Limited | 0.10% | 5ml | eye drops | per ml | KES 73 |
| Probeta | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 0.10% | 7.5ml | eye drops | per ml | KES 72.00 |
| Probeta | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 5g | eye ointment | KES 74.25 |
| 12. Betamethasone Valerate | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Relief of some inflammatory conditions when potentially less harmful measures are ineffective |
| Precautions | Limit use in children or on face to maximum of 5 days. It should be withdrawn gradually following prolonged therapy. Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci. |
| Contra-Indications | Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use. |
| Side Effects | Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension. |
| Dosage | Apply sparingly BD or TID |
| Drug Category | DERMATOLOGICAL PREPARATIONS |
| Drug Sub-Category | Topical Corticosteroids |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Advantan | Bayer Schering Pharma | Bayer East Africa Ltd. | 0.1% | 15gm | Cream | KES 499.75 | |
| Advantan | Bayer Schering Pharma | Bayer East Africa Ltd. | 0.1% | 15gm | Ointment | KES 499.75 | |
| Beclasone C | Emcure Pharmaceuticals Limited | Syner-Medica (K) Ltd | 15gm | Cream | KES 80 | ||
| Beclasone N | Emcure Pharmaceuticals Limited | Syner-Medica (K) Ltd | 15gm | Cream | KES 80 | ||
| Bentopic | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 0.10% | 15gm | Ointment | KES 35.00 | |
| Betaderm | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 0.10% | 15gm | Cream | KES 29.70 | |
| Betaderm | ATCO Laboratories (Pvt) Ltd | Globe Pharmacy Ltd., | 15gm | Ointment | KES 32.4 | ||
| Betamed | Medivet Products Ltd | Medivet Products Ltd. | 0.10% | 15gm | Ointment | KES POR | |
| Betamed | Medivet Products Ltd | Medivet Products Ltd. | 0.10% | 15gm | Cream | KES POR | |
| Betason | Pharmaceuticals Manufacturing Co. k Ltd. | Pharmaceutical Manufacturing Co.(K) Ltd | 0.10% | 15gm | Cream | KES 36.00 | |
| Betason | Pharmaceuticals Manufacturing Co. k Ltd. | Pharmaceutical Manufacturing Co.(K) Ltd | 0.10% | 15gm | Ointment | KES 40.00 | |
| Betaven | OSS-Chemie k Ltd | Njimia Pharmaceuticals Ltd. | 0.10% | 15gm | Ointment | KES 37.00 | |
| Betaven | OSS-Chemie k Ltd | Njimia Pharmaceuticals Ltd. | 0.10% | 15gm | Cream | KES 35.00 | |
| Betcosyl | Cosmos Limited. | Cosmos Limited | 0.10% | 15gm | Cream | KES 80.00 | |
| Betnovate | GlaxoSmithkline | GlaxoSmithKline | 0.10% | 15gm | Cream | KES 256.20 | |
| Betnovate | GlaxoSmithkline | GlaxoSmithKline | 0.10% | 30gm | Ointment | KES 387.80 | |
| Celestoderm V | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.10% | 15gm | Ointment | KES 208 | |
| Celestoderm V | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.10% | 15gm | Cream | KES 208 | |
| Celestone | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.5mg | 30 | Tablet | per tablet | KES 370 |
| Celestone | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 4mg | 1ml | Injection | per ml | KES 318 |
| Clo-sol | Devang Pharmaceuticals Limited | Eurox Pharmaceuticals Ltd. | 0.05% | 15gm | Cream | KES 100 | |
| Clo-sol | Devang Pharmaceuticals Limited | Eurox Pharmaceuticals Ltd. | 0.05% | 15gm | Ointment | KES 100 | |
| Cosvate-G | Cosme Pharma Ltd | Surgilinks Ltd. | 0.1%/0.5% | 15gm | Cream | KES 110 | |
| Dawavate | Dawa Limited | Dawa Limited | 0.10% | 15gm | Cream | KES 28.00 | |
| Elyvate | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 0.10% | 15gm | Ointment | KES 35.00 | |
| Elyvate | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 0.10% | 15gm | Cream | KES 35.00 | |
| Hydrocosyl® | Cosmos Limited. | Cosmos Limited | 1% | 15gm | Cream | KES 60 | |
| Hydrocosyl® | Cosmos Limited. | Cosmos Limited | 1% | 15gm | Ointment | KES 60 | |
| Kemzid | Unison Laboratories | Omaera Pharmaceuticals Ltd | 1% | 15gm | Cream | KES 144 | |
| Laeovate | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 0.10% | 15gm | Ointment | KES 45.00 | |
| Laeovate | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 0.10% | 15gm | Cream | KES 45.00 | |
| Maxobeta | Macs Pharmaceuticals | Mac?s Pharmaceuticals Ltd | 0.10% | 15gm | Ointment | KES 36.00 | |
| Maxobeta | Macs Pharmaceuticals | Mac?s Pharmaceuticals Ltd | 0.10% | 15gm | Cream | KES 36.00 | |
| Mediven | Regal Pharmaceuticals | Regal Pharmaceuticals Limited | 0.10% | 15gm | Ointment | KES 79.00 | |
| Mediven | Regal Pharmaceuticals | Regal Pharmaceuticals Limited | 0.10% | 15gm | Cream | KES 78.00 | |
| Unibet | Universal Pharmaceuticals Ltd. | Europa Healthcare Ltd. | 0.10% | 15gm | Cream | KES 43 |
| 13. Betamethasone Valerate/ Fusidic Acid | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Steroid responsive dermatoses complicated or likely to be complicated by bacterial infections |
| Precautions | Limit use in children or on face to maximum of 5 days. It should be withdrawn gradually following prolonged therapy. Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci. |
| Contra-Indications | Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use. |
| Side Effects | Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension. |
| Dosage | Apply sparingly BD or TID |
| Drug Category | DERMATOLOGICAL PREPARATIONS |
| Drug Sub-Category | Topical Steroid/ Antibacterials |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Fucicort | Leo Pharmaceuticals | Jos Hansen (E.A) Ltd | 0.1%/2% | 15gm | Cream | KES 554 | |
| Zynex | DWD | Lords Healthcare Ltd. | 0.1%/2% | 10gm | Cream | KES 350 | |
| Fucivate | Biopharma Laboratories Ltd. | Maxim Pharmaceuticals Ltd | 0.1%/2% | 10gm | Cream | KES 200.00 |
| 14. Betamethasone Valerate/ Neomycin | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Steroid responsive dermatoses complicated or likely to be complicated by bacterial infections |
| Precautions | Limit use in children or on face to maximum of 5 days. It should be withdrawn gradually following prolonged therapy. Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci. |
| Contra-Indications | Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use. |
| Side Effects | Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension. |
| Dosage | Apply sparingly BD or TID |
| Drug Category | DERMATOLOGICAL PREPARATIONS |
| Drug Sub-Category | Topical Steroid/ Antibacterials |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Betason-N | Pharmaceuticals Manufacturing Co. k Ltd. | Pharmaceutical Manufacturing Co.(K) Ltd | 0.1%/0.5% | 15gm | Cream | KES 90.00 | |
| Betason-N | Pharmaceuticals Manufacturing Co. k Ltd. | Pharmaceutical Manufacturing Co.(K) Ltd | 0.1%/0.5% | 15gm | Ointment | KES 90.00 | |
| Betaven-N | OSS-Chemie k Ltd | Njimia Pharmaceuticals Ltd. | 0.1%/0.5% | 15gm | Cream | KES 61.00 | |
| Betaven-N | OSS-Chemie k Ltd | Njimia Pharmaceuticals Ltd. | 0.1%/0.5% | 15gm | Ointment | KES 64.00 | |
| Betnovate-N | GlaxoSmithkline | GlaxoSmithKline | 0.1%/0.5% | 15gm | Cream | KES 173.00 | |
| Betnovate-N | GlaxoSmithkline | GlaxoSmithKline | 0.1%/0.5% | 15gm | Ointment | KES 173.00 | |
| Diprovate | Ranbaxy Laboratories | Pharma Specialities Ltd. | 0.1%/0.5% | 15gm | Cream | KES 90.00 | |
| Diprovate | Ranbaxy Laboratories | Pharma Specialities Ltd. | 0.1%/0.5% | 15gm | Ointment | KES 90.00 | |
| Netasole | Centaur Pharmaceuticals Ltd. | Sai Pharmaceuticals Ltd. | 0.1%/0.5% | 15gm | Cream | KES 61.00 |
| 15. Betamethasone Valerate/Gentamycin | |
|---|---|
| Mode Of Action | It diffuses across cell membranes and forms a complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, binds to DNA, and stimulate transcription of messenger RNA (mRNA). Messenger RNA leads to protein synthesis of various enzymes that are responsible for the effects of systemic corticosteroids |
| Drug Indication | Steroid responsive dermatoses complicated or likely to be complicated by bacterial infections |
| Precautions | Limit use in children or on face to maximum of 5 days. It should be withdrawn gradually following prolonged therapy. Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci. |
| Contra-Indications | Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use. |
| Side Effects | Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension. |
| Dosage | Apply sparingly BD or TID |
| Drug Category | DERMATOLOGICAL PREPARATIONS |
| Drug Sub-Category | Topical Steroid/ Antibacterials |
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Bentogen | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 0.1%/0.1% | 15gm | Ointment | KES 60.00 | |
| Bentogen | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 0.1%/0.1% | 15gm | Cream | KES 60.00 | |
| Betason-G | Pharmaceuticals Manufacturing Co. k Ltd. | Pharmaceutical Manufacturing Co.(K) Ltd | 0.1%/0.1% | 15gm | Ointment | KES 90.00 | |
| Celestoderm with Garamycin | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 0.1%/0.1% | 15gm | Ointment | KES 421 | |
| Dawavate G | Dawa Limited | Dawa Limited | 0.1%/0.1% | 15gm | Ointment | KES 65 | |
| Elyvate G | Elys Chemicals Industries Ltd. | Elys Chemical Industries Ltd. | 0.1%/0.1% | 15gm | Ointment | KES 65 |